A Phase II Clinical Trial of Anti-Tac (Fv)-PE38 (LMB-2) Immunotoxin for CD25 Positive Hairy Cell Leukemia.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Anti-Tac Fv PE38 conjugate (Primary)
- Indications Hairy cell leukaemia
- Focus Therapeutic Use
- 05 May 2021 Biomarkers information updated
- 07 Jun 2011 Planned end date changed from 1 Apr 2011 to 1 Apr 2014 as reported by ClinicalTrials.gov.
- 07 Jun 2011 Planned end date changed from 1 Apr 2011 to 1 Apr 2014 as reported by ClinicalTrials.gov.